Navigation Links
Expansion of monocyte subset could serve as a biomarker for HIV progressions
Date:3/27/2008

An increase in the CD163+/CD16+ monocyte subset could be a biomarker for the progression of HIV disease, according to researchers at Temple University.

The researchers reported their findings, CD163/CD16 Coexpression by Circulating Monocytes/Macrophages in HIV: Potential Biomarkers for HIV Infection and AIDS Progression, in the March issue of AIDS Research and Human Retroviruses (www.liebertonline.com/aid).

A monocyte is a specific white blood cell, a part of the human bodys immune system that protects against blood-borne pathogens and moves quickly to sites of infection within the bodys tissues. As monocytes enter tissue, they undergo a series of changes to become macrophages.

The researchers were investigating alterations in this monocyte subset in patients with HIV infection. As part of this study, they examined a cohort of 18 patients from the Comprehensive HIV Program at Temple University Hospital, under the direction of Ellen Tedaldi, and seven individuals without HIV infection.

At first, we were just looking at whether or not we saw alterations in this CD163+/CD16+ subset and whether it might be reflective of the amount of virus they have in circulation, said Tracy Fischer-Smith, an associate scientist in Temples Neuroscience Department and the studys lead author. We did, indeed, find that patients with detectable virus had an increase of this monocyte subset that correlated with the amount of virus they had in their blood. We were surprised to find that patients with CD4+ T cell counts of less than 450 cells per microliter [200 or less per microliter is defined as AIDS], the increase of this monocyte subset correlates inversely with the number of T cells.

Fischer-Smith said this finding suggests that as the monocyte cells are increasing, these patients are losing CD4+ T cells, which are critical for the maintenance of immunological competence.

This may actually provide an earlier window into what is happening with HIV-infected patients where we might be able to see that immune impairment is taking place before we see a dramatic loss of CD4+ T cells, she said.

It looks like, based on these correlations, that this particular cell type may be involved in immune impairment and the progression of HIV, said Jay Rappaport, professor of neuroscience and neurovirology, who oversaw the study. Is it a good prognostic indicator" If you have a lot of these monocytes, does it mean you are going to progress into AIDS faster" Right now, all we know is what the correlations are, he said.

Rappaport added that he believes the CD163+/CD16+ monocyte subset is the first biomarker that correlates with viral load and CD4+ count. The fact that it actually correlates with both, we think, might make it a key cell type in the pathogenesis of AIDS. Fischer-Smith said the researchers plan to expand this study by following a cohort of patients longitudinally to see if their findings really can provide doctors with an early warning system and help to design better therapeutic strategies.

When you are just looking at a single time-point, you dont know how changes in this monocyte subset might occur over time, and how these changes might relate to the viral load and T cell number in individual patients, she said. That is why we want to investigate this further with a longitudinal study of HIV patients.


'/>"/>

Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-4380
Temple University
Source:Eurekalert

Related medicine news :

1. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
2. Phillies Pitcher Jamie Moyer and Wife Karen Continue National Expansion - Bringing Bereavement Camps for Kids to Every Major League Baseball City
3. Heart Hospital of Austins Expansion Increases Patient Capacity by 30 Percent
4. Expansion Will Double Size of The Heart Center at Regions Hospital
5. Sikorsky Aircraft and PHI Celebrate Fleet Expansion and 20K Milestone at Heli-Expo
6. ADAMS Performs Management Services for University Hospitals $600 Million Expansion/Renovation Program in Cleveland, OH
7. MedCath Plans 60-bed Expansion at TexSAn Heart Hospital
8. Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs
9. Ingenious Med Reports Record Sales and Client Expansions in 2007
10. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
11. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with ... at 1:00 pm ET. This conference discusses strategies to prevent readmissions in light ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, ... Spice", it has been used for thousands of years. , "The West has caught ... of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... NetZoom subscribers can request new equipment shapes for free and download shapes and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... its market value in 2016. There are currently three proton therapy centers ... to treat more patients. In Italy , the first ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
Breaking Medicine Technology: